ECOG Performance Status
The Eastern Cooperative Oncology Group (ECOG) performance status is a scale used to assess how a patient’s disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis.
Brief Fatigue Inventory
The Brief Fatigue Inventory is a simple yet sensitive tool that allows the severity and impact of cancer-related fatigue to be assessed.
Supportive care
No publications this month related to supportive care in myeloma
Diagnostic tests and prognostic indicators
Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden. Giles SL et al. Clin Radiol. 2015 Mar 19. pii: S0009-9260(15)00074-4. doi: 10.1016/j.crad.2015.02.013. [Epub ahead of print]. The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs. Franssen LE et al. Bone Marrow Transplant. 2015 Mar 23. doi: 10.1038/bmt.2015.48.…
DetailsRelated conditions
Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens. Bochtler T et al. J Clin Oncol. 2015 Mar 16. pii: JCO.2014.57.4947. [Epub ahead of print]. Extracorporeal Membrane Oxygenation as Bridge-to-Decision in Acute Heart Failure due to Systemic Light-Chain Amyloidosis. Mancio Silva J et al. Am J Case Rep. 2015 Mar 24;15:174-81.…
DetailsEmerging treatments
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Seggewiss-Bernhardt R et al. Cancer. 2015 Mar 24. doi: 10.1002/cncr.29339. [Epub ahead of print]. O7.3BET-bromodomain (BRD) inhibitor OTX015: Final results of the dose-finding part of a phase I study in hematologic malignancies. Herait…
DetailsBiology and Genetics
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. Kikuchi S et al. Leukemia. 2015 Mar 24. doi: 10.1038/leu.2015.83. [Epub ahead of print]. Structure-activity relationships of benzhydrol derivatives based on 1′-acetoxychavicol acetate (ACA) and their inhibitory activities on multiple myeloma cell growth via inactivation of the NF-κB pathway. Misawa T et al. Bioorg Med Chem. 2015 Mar 7. pii: S0968-0896(15)00143-1. doi:…
Details